Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
Pulmonary arterial hypertension (PAH) is a severe, progressive and potentially fatal disease
that impairs the pulmonary circulation and leads to right ventricular failure. One of the
world most prevalent etiologies of PAH is schistosomiasis-associated pulmonary arterial
hypertension (Sch-PAH). New drugs have emerged to treat other forms of PAH, but their
benefits cannot be automatically translated for Sch-PAH patients, since this etiology was not
included in the pivotal PAH trials. One of the most promising therapies for the treatment of
PAH to emerge in recent years is selexipag, an oral IP receptor agonist, which acts on the
prostacyclin pathway. The present study aims to evaluate the efficacy, safety and
tolerability of selexipague for the treatment of schistosomiasis-associated pulmonary
arterial hypertension.